decline and loss of independence. 3 , 4 Moreover, hospitalization is associated with increased healthcare expenses and a significant financial burden for older adults with cancer and their families. 5 – 7 Identification of validated risk factors for
Search Results
Mostafa R. Mohamed, Kah Poh Loh, Supriya G. Mohile, Michael Sohn, Tracy Webb, Megan Wells, Sule Yilmaz, Rachael Tylock, Eva Culakova, Allison Magnuson, Can-Lan Sun, James Bearden, Judith O. Hopkins, Bryan A. Faller, and Heidi D. Klepin
Paul S. White, Michael Dennis, Eric A. Jones, Janice M. Weinberg, and Shayna Sarosiek
-institution retrospective study, we sought to identify the prevalence of hypocalcemia and determine the risk factors for development of hypocalcemia in a diverse, multiracial population of patients with cancer receiving treatment with BMAs. Patients and Methods We performed
Adam J. Olszewski, Kalyan C. Mantripragada, and Jorge J. Castillo
risk factors for death and hospitalization during the first month of rituximab-based immunochemotherapy using population-based data from Medicare beneficiaries. Patients and Methods Data Source and Cohort Selection This study used
Michael B. Streiff, Bjorn Holmstrom, Dana Angelini, Aneel Ashrani, Amro Elshoury, John Fanikos, Kleber Yotsumoto Fertrin, Annemarie E. Fogerty, Shuwei Gao, Samuel Z. Goldhaber, Krishna Gundabolu, Ibrahim Ibrahim, Eric Kraut, Andrew D. Leavitt, Alfred Lee, Jason T. Lee, Ming Lim, Janelle Mann, Karlyn Martin, Brandon McMahon, John Moriarty, Colleen Morton, Thomas L. Ortel, Rita Paschal, Jordan Schaefer, Sanford Shattil, Tanya Siddiqi, Deepak Sudheendra, Eliot Williams, Liz Hollinger, and Mai Q. Nguyen
update of the NCCN Guidelines are available at NCCN.org. VTE Risk Assessment in Patients With Cancer VTE risk factors in patients with cancer can be grouped into 3 general categories: patient-related factors, cancer-related factors, and treatment
Jeremy Lund, Angela Pearson, and Georgia Keriazes
call for a multidisciplinary, coordinated effort to identify potential risk factors for readmission. 2 With the recent changes to repayment structures by CMS for selected diagnoses and the prospect of that list growing, it is imperative for
Fangwen Zou, Hamzah Abu-Sbeih, Weijie Ma, Yuanzun Peng, Wei Qiao, Jianbo Wang, Amishi Y. Shah, Isabella C. Glitza Oliva, Sarina A. Piha-Paul, John A. Thompson, Hao Chi Zhang, Anusha S. Thomas, and Yinghong Wang
the risk factors for chronic IMDC or its effects on the overall cancer outcome. We attempted to bridge this knowledge gap in a retrospective study of patients with advanced malignancies at The University of Texas MD Anderson Cancer Center (MDACC
Mohammad Abu Zaid, Wambui G. Gathirua-Mwangi, Chunkit Fung, Patrick O. Monahan, Omar El-Charif, Annalynn M. Williams, Darren R. Feldman, Robert J. Hamilton, David J. Vaughn, Clair J. Beard, Ryan Cook, Sandra K. Althouse, Shirin Ardeshir-Rouhani-Fard, Paul C. Dinh Jr, Howard D. Sesso, Lawrence H. Einhorn, Sophie D. Fossa, Lois B. Travis, and for the Platinum Study Group
disease (CVD) compared with controls. 8 – 13 In the general population, metabolic syndrome (MetS) is a major risk factor for CVD. 14 MetS is a constellation of interrelated CVD risk factors, including insulin resistance, hypertension, elevated
Derek Weycker, Xiaoyan Li, Rich Barron, Hongsheng Wu, P.K. Morrow, Hairong Xu, Maureen Reiner, Jacob Garcia, Shivani K. Mhatre, and Gary H. Lyman
-stimulating factor (CSF) when risk, based on the chemotherapy regimen and patient risk factors, is “high” (>20%) (to view the most recent version of these guidelines, visit NCCN.org ). For patients whose risk is high based on the chemotherapy regimen alone, the
Angel Qin, Songzhu Zhao, Abdul Miah, Lai Wei, Sandipkumar Patel, Andrew Johns, Madison Grogan, Erin M. Bertino, Kai He, Peter G. Shields, Gregory P. Kalemkerian, Shirish M. Gadgeel, Nithya Ramnath, Bryan J. Schneider, Khaled A. Hassan, Nicholas Szerlip, Zoey Chopra, Sara Journey, Jessica Waninger, Daniel Spakowicz, David P. Carbone, Carolyn J. Presley, Gregory A. Otterson, Michael D. Green, and Dwight H. Owen
summarized and compared between those with and without SREs using the Fisher exact test for the categorical risk factors and the Kruskal-Wallis test for the continuous variables. All statistical analyses were performed using SAS, version 9.4 (SAS Institute
Mikkael A. Sekeres
be an overestimate, a rate of 60,000 people likely underestimates the impact of the disease. Risk Factors for Developing MDS The greatest risk factor for developing MDS is advanced age, with yearly incidence rates increasing 10-fold for
